Blood Samples Study of Rituximab and Ocrelizumab in Relapsing Multiple Sclerosis
Studies blood levels of rituximab and ocrelizumab in adults with relapsing-remitting multiple sclerosis.
Plain-language title generated from the registry record
Registry title: Rituximab and Ocrelizumab in Serum With Multiple Sclerosis
Key facts
- Where
- Bergen, NorwaySee the site
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 60 years old?
Source: NCT06663111, who can take part
Where in Norway
- Haukeland University Hospital, Deparment of medical biochemistry and pharmacologyBergen, NorwayTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Haukeland University Hospital
- Trial code
- NCT06663111
- Record updated
- 29 October 2024
- Original description
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.Read full original descriptionShow less
Rituximab and Ocrelizumab in Serum With Multiple Sclerosis (ROS-MS)
ROS-MS is a clinical pharmacological substudy to the OVERLORD-MS study (NCT04578639), designed to examine the possibilities of personalized treatment with rituximab and ocrelizumab in patients with relapsing-remitting multiple sclerosis.
Inclusion: Included in OVERLORD-MS (NCT04578639); Willing to attend laboratory for blood sample collection at scheduled time points.
Exclusion: Not willing to attend laboratory for blood sample collection at scheduled time points.